According to a report from Politico, EC Commissioner Margrethe Vestager is weighing up whether there are grounds to open a probe into Facebook’s European tax arrangements as the Commission deepens its multinational investigation into sweetheart tax deals.
Vestager stressed that her work on taxes is unfinished, and two people close to the work of the competition investigators said that they had now turned their attention to Facebook’s arrangements. A third person agreed that the Commission was looking into these, but predicted that Vestager’s team would not find enough to open a formal investigation into the social networking giant.
At a press conference at the Web Summit in Lisbon on Wednesday, November 7, Vestager was asked whether her department was specifically looking into an Irish arrangement that allows investors to lower their tax burden by offsetting costs from intellectual property assets they have acquired.
“We continue to ask questions. We’re asking Member States for evidence of tax rulings about specific cases,” she said. “So far, we have no specific criticism of any legislation from the Irish Republic.”
Vestager and the Commission ruled in 2016 that Ireland would have to collect €13 billion (US$ billion)in unpaid taxes from Apple.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan